Recursion Pharmaceuticals (RXRX) Change in Receivables (2020 - 2021)

Recursion Pharmaceuticals' (RXRX) quarterly Change in Receivables came in at -$16000.0 in Q3 2021, down 100.05% YoY from $30.2 million in Q3 2020, and down 23.08% on a QoQ basis from -$13000.0 in Q2 2021.

Recursion Pharmaceuticals (RXRX) Change in Receivables (2020 - 2021) Analysis & Trends

Recursion Pharmaceuticals (RXRX) has 2 years of Change in Receivables data on file, last reported at -$16000.0 in Q3 2021.

  • Quarterly Change in Receivables fell 100.05% year-over-year to -$16000.0 in Q3 2021, while the trailing twelve-month figure through Dec 2021 was -$114000.0 (down 2380.0% YoY) and the FY2021 annual result came in at -$114000.0, down 2380.0% from the prior year.
  • Change in Receivables retreated to -$16000.0 in Q3 2021, from -$13000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $30.2 million in Q3 2020 to a low of -$30.0 million in Q4 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 140.20 Mn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 838.50 Mn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 117.58 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -483,662.49
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 31.60 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 37.16 Mn
10 Recursion Pharmaceuticals 1.69 Bn 1.14 Bn -3.82 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2021 -16,000.00
Sep 30, 2021 -16,000.00
Jun 30, 2021 -13,000.00
Jun 30, 2021 -13,000.00
Mar 31, 2021 -85,000.00
Mar 31, 2021 -85,000.00
Dec 31, 2020 -30.04 Mn
Dec 31, 2020 -30.04 Mn
Sep 30, 2020 30.19 Mn
Sep 30, 2020 30.19 Mn
Jun 30, 2020 -60,000.00
Jun 30, 2020 -60,000.00
Mar 31, 2020 -82,000.00
Mar 31, 2020 -82,000.00